International trade can to some extent be explained by the theory of absolute and comparative advantage. By nature, countries have distinctive immobile production factors and hence different relative production costs for the same good/service (Lawler and Seddighi, 2001). The theory of the absolute advantage by Adam Smith is that a country should specialise on the product/service where it has an absolute advantage over any other country in order to increase productivity and output.
Ricardo’s theory of the comparative advantage says a country should export products where it has the greatest comparative advantage or where the comparative disadvantage is smallest and should import goods in which its comparative disadvantage is greatest (Trebilcock and Howse, 2005). This model still represents the basis for international trade theory, but it was further modified and reformulated which will be discussed later on.
The pharmaceutical industry in Switzerland by looking at innovation, R&D expenditure, export figures and the growth level will be analysed. All this is interrelated to theoretical background of newer trade theories of Vernon, Krugman and Cantwell.
Table of Contents
1. Introduction
2. The pharmaceutical industry in Switzerland
3. Conclusion
4. List of References
5. Appendices
Objectives and Topics
The primary objective of this work is to analyze the pharmaceutical industry in Switzerland by examining key economic indicators such as innovation performance, R&D expenditure, export figures, and growth levels, while situating these findings within modern international trade theories.
- Analysis of Switzerland's innovation capacity and patent activity.
- Evaluation of R&D investment trends within the Swiss pharmaceutical sector.
- Examination of Switzerland's foreign trade performance and export surpluses.
- Comparison of empirical data with established trade theories, specifically those of Vernon, Krugman, and Cantwell.
- Discussion on the strategic importance of the pharmaceutical industry for Swiss economic prosperity.
Excerpt from the Book
1. Introduction
International trade can to some extent be explained by the theory of absolute and comparative advantage. By nature, countries have distinctive immobile production factors and hence different relative production costs for the same good/service (Lawler and Seddighi, 2001). The theory of the absolute advantage by Adam Smith is that a country should specialise on the product/service where it has an absolute advantage over any other country in order to increase productivity and output.
Ricardo’s theory of the comparative advantage says a country should export products where it has the greatest comparative advantage or where the comparative disadvantage is smallest and should import goods in which its comparative disadvantage is greatest (Trebilcock and Howse, 2005). This model still represents the basis for international trade theory, but it was further modified and reformulated which will be discussed later on.
In the following I am analyzing the pharmaceutical industry in Switzerland by looking at innovation, R&D expenditure, export figures and the growth level. All this is interrelated to theoretical background of newer trade theories of Vernon, Krugman and Cantwell.
Summary of Chapters
1. Introduction: This chapter outlines the theoretical foundations of international trade, specifically absolute and comparative advantage, and introduces the focus on the Swiss pharmaceutical industry.
2. The pharmaceutical industry in Switzerland: This chapter provides a comprehensive empirical analysis of the sector, covering R&D expenditure, innovation metrics, and export data, while contrasting these with trade theories like the Product Cycle Model.
3. Conclusion: This chapter synthesizes the main findings, emphasizing the critical link between high R&D investment, export competitiveness, and long-term economic prosperity for Switzerland.
4. List of References: This section provides a complete bibliography of the books, journals, and electronic sources utilized in the study.
5. Appendices: This section contains supplementary data, including statistical tables and graphs regarding global R&D rankings and Swiss trade composition.
Keywords
Pharmaceutical industry, Switzerland, International trade, Innovation, Research and Development, R&D expenditure, Comparative advantage, Product Cycle Model, Patents, Export surplus, Economic growth, Technology transfer, Foreign Direct Investment, Competitiveness, Globalization.
Frequently Asked Questions
What is the core focus of this research paper?
The paper focuses on the performance and economic significance of the pharmaceutical industry in Switzerland, evaluating its role as a driver for national economic prosperity and innovation.
What are the central thematic areas covered?
The central themes include R&D intensity, global patent activity, export trade balance, the influence of multinational corporations, and the application of trade theories to a knowledge-driven sector.
What is the primary research objective?
The objective is to analyze why the pharmaceutical industry is a cornerstone of the Swiss economy by investigating its R&D and export statistics and applying the theories of Vernon, Krugman, and Cantwell.
Which scientific methodology is applied?
The study utilizes a descriptive and analytical approach, relying on empirical data from organizations like the OECD, the Swiss Federal Statistical Office, and academic literature to support theoretical discussions.
What topics are discussed in the main body?
The main body examines the global and national market shares of Swiss pharmaceutical companies, the importance of patents, trends in R&D investment, and how these factors influence Switzerland's foreign trade balance.
Which keywords best characterize this work?
Key terms include pharmaceutical industry, Switzerland, R&D expenditure, innovation, comparative advantage, and international trade theory.
How does the author view the applicability of Vernon's Product Cycle Model?
The author notes that while Vernon's model provides a useful starting point, it is less applicable to the research-intensive pharmaceutical industry than it is to general manufacturing, due to the industry's unique reliance on continuous innovation and specialized markets.
Why does the pharmaceutical industry invest heavily abroad?
According to the text, Swiss firms invest abroad to secure proximity to key markets, access leading universities and qualified staff, and tap into local knowledge sources to maintain overall competitiveness.
What is the role of patent protection in this sector?
Patent protection is described as critical for profitability and sustained growth, providing companies the necessary incentive to invest the massive financial resources (roughly 1 billion USD per product) required for development over 10-15 years.
- Quote paper
- Nicole Burkardt (Author), 2007, The pharmaceutical industry in Switzerland, Munich, GRIN Verlag, https://www.grin.com/document/80195
